All Content Outsourced Pharma

  1. ADC Heterogeneity, Site-Specific Conjugation 4/29/2025

    This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipophilic toxicity, homogeneity, computational tools to address molecular design and ADC behavior, and revisiting strategic considerations in CDMO selection before addressing a second live poll of our audience. 

  2. Linker And ADC Platform Manufacturing Technologies 4/29/2025

    In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Biotech) answer audience questions about the feasibility of developing a platform for ADC development, IP considerations for proprietary technologies, and outsourcing vs. in-house manufacturing approaches.

  3. Challenges In ADC Process Development 4/29/2025

    Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) address audience questions on target identification cleanliness and payload challenges before we turn the tables on the audience with a question on their biggest challenges.

  4. AI In ADC Target Identification 4/29/2025

    How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clinical implications of target expression and internalization, and AlphaFold AI-driven pathology in this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development.

  5. ADCs & Speed To IND 4/29/2025

    In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC development challenges—including molecular complexity, regulatory and analytical hurdles, and strategic logistical manufacturing. We discuss those challenges in the context of the burgeoning industry’s breakneck development timelines leading up to IND submission.

  6. Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development 4/29/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production.

  7. RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell & Exosome Therapy Manufacturing 4/29/2025

    RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.

  8. Protein Stress Testing 4/28/2025

    Start your forced degradation studies early to uncover molecular risks, strengthen product stability, and ensure regulatory-ready development from the start.

  9. Analytical Development Services 4/28/2025

    Understand the basic principles of analytical development for cGMP assays and the assays that are generally relevant to major biopharmaceutical modalities.

  10. Stability Services 4/28/2025

    Dive into a summary of stability considerations and process examples for recombinant proteins, mAbs, gene therapy, and subunit vaccines.